FINDING A PATH

FOR FAMILIES WITH HEREDITARY CANCER

Lynch syndrome is the most common cause of hereditary cancers but one of the most difficult to diagnose. Lynsight’s validated assay, DiagMMR, offers a new way to test for Lynch syndrome, so healthcare providers can focus on the path instead of the problem.

FORWARD

What is DiagMMR?

Predictive, Not Reactive

DiagMMR detects MMR deficiency from a minimally invasive, non-malignant tissue sample – before tumors appear. 

Functional Test 

Lynch syndrome testing is done directly on patient cells. Because we extract proteins from patient cells, we don’t need to know the underlying variant. 

Actionable Results

While DNA sequencing returns results faster, interpretations can take 6-8 weeks or more. DiagMMR test results are available in 4 weeks and don’t require interpretation – helping patients and families take their next steps faster. 

Copyright © 2024 Lynsight. All rights reserved.

For Providers

Early detection is key to effectively managing Lynch syndrome and reducing the risk of associated cancers. By utilizing DiagMMR testing, healthcare providers can identify at-risk individuals early on, allowing for timely intervention, proactive surveillance and personalized risk management strategies.

For Patients & Families 

When patients and their families can get an early answer about Lynch syndrome, they can get a head start on prevention strategies and ahead of early signs of cancer. DiagMMR provides higher fidelity results so that patients and families know their risk and can plan accordingly. 

For Payers

DiagMMR empowers individuals to take proactive steps for their health. Early detection means early intervention, leading to fewer hospital visits, fewer treatments, and, ultimately, lower healthcare costs for all.

Find A Path Forward

+358 40 6602622

LYNSIGHTLABS.COM

Arabiankatu 12
00560 Helsinki, Finland

FIND A PATH FORWARD

Lynsight has been on the forefront of Lynch syndrome research for over 10 years, driven by the mission to find a better way to help people prevent cancer. Originating in the labs of the University of Helsinki in the 1990s, Lynsight’s relentless pursuit to provide the most precise Lynch syndrome diagnostics continues every day. 

The company is committed to ensuring that every potential Lynch syndrome case is tested.

Founded by the Leaders

IN LYNCH SYNDROME RESEARCH

Lynch syndrome is the most common cause of hereditary cancers but one of the most difficult to diagnose. Lynsight’s validated assay, DiagMMR, offers a new way to test for Lynch syndrome, so healthcare providers can focus on the path instead of the problem.

What is 

DiagMMR?

Arabiankatu 12 00560 Helsinki, Finland

Founded by the Leaders

Sign up for our newsletter!